MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

January 28, 2019

Primary Completion Date

April 24, 2020

Study Completion Date

December 31, 2029

Conditions
Relapsing-Remitting Multiple Sclerosis (RRMS)
Interventions
DRUG

IMU-838 (30 mg/day)

"* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned dose which consists of two 15 mg tablets IMU-838 once daily."

DRUG

IMU-838 (45 mg/day)

"* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 22.5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 22.5 mg tablets once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 45 mg/day dose will take the full assigned dose of two 22.5 mg tablets IMU-838 once daily."

DRUG

Placebo

"* Main treatment period (Cohort 1 and Cohort 2): All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards.~* Optional extended treatment period: Placebo not applicable as participants were re-randomized to a 30 mg/day dose or a 45 mg/day dose."

DRUG

IMU-838 (10 mg/day)

"* Main treatment period for Cohort 2: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 5 mg tablets once daily).~* Optional extended treatment period (not applicable to Cohort 2): IMU-838 10 mg/day not applicable."

Trial Locations (38)

1113

"MHATNP Sveti Naum EAD, Neurology Clinic for Movement Disorders, First Department of Neurology Diseases", Sofia

"MHATNPsy Sveti Naum EAD, Intensive Therapy Clinic Of Neurology Diseases", Sofia

1408

"DCC Neoclinic EAD, Cabinet Neurology Diseases", Sofia

1431

"UMHAT Alexandrovska EAD, Clinic of Neurology Diseases, Department of Inherited Degenerative and Immunoinflamatori Diseases at Peripheral Nervous System", Sofia

"UMHAT Sveti Ivan Rilski EAD Sofia Clinic of Neurological Diseases", Sofia

"UMHATAlexandrovskaEAD, Department of Degenerative and Immunoinflamatory Disease of the Central Nervous System", Sofia

1606

Central Clinical Base-Medical Institute - Ministry of Interior, Neurology Clinic, Sofia

Military Medical Academy - Sofia, Clinic of Neurology Diseases, Sofia

Military Medical Academy, Clinic of Functional Diagnostics of Nevous System, Sofia

2700

MHAT Pulse AD, Department of Neurology Diseases, Blagoevgrad

4001

"UMHAT Kaspela EOOD, Department of Neurology Diseases", Plovdiv

5800

"UMHAT Dr.Georgi Stranski EAD Pleven Department of Professional Diseases", Pleven

5804

"MHAT Heart and brain EAD Pleven Department of Neurology Diseases", Pleven

7002

"UMHAT Kanev Ruse, Department of General and Vascular Neurology", Rousse

9010

"UMHAT Sveta Marina EAD, First Neurology Clinic", Varna

14029

Chernihiv Regional Hospital, Department of Neurology, Chernihiv

21005

Vinnytsya Regional Psychoneurology Hospital n.a. Yushchenko, Department of Neurology #3, Vinnytsia

36011

Poltava Regional Clinical Hospital n.a. Sklifosovskyi, Department of Neurology, Poltava

43005

Volyn Regional Clinical Hospital, Department of Neurology, Lutsk

49000

Dnipropetrovsk Municipal Hospital #5, Neurological Department of the inflammatory and demyelinating diseases of CNS, Dnipro

49027

Ukrainian State Research Institute of Medical and Social Problems of Disability of MOH of Ukraine, Dnipro

61000

Kharkiv Regional Clinical Hospital, Department of Neurology, Kharkiv

61068

Institute of Neurology, Psychiatry and Narcology NAMSU, Kharkiv

69068

City Clinical Hospital #2, Department of Neurology, Zaporizhzhya

69600

Zaporizhzhya Regional Clinical Hospital, Department of Neurology #1, Zaporizhzhya

76000

Regional Clinical Hospital, Department of vascular Neurology, Ivano-Frankivsk

88018

Regional Clinical Centre of Neurosurgery and Neurology, Department #2, Uzhhorod

900123

Spitalul Clinic Cai Ferate Constanta, Constanța

85-065

Nasz Lekarz Ośrodek Badań Klinicznych, Bydgoszcz

85-796

Specjalistyczna Praktyka Lekarska Paweł Bochniak, Bydgoszcz

20-016

Indywidualna Praktyka Lekarska Prof. Konrad Rejdak, Lublin

05-830

BioResearch Group Sp. Z o.o, Nadarzyn

01-684

Centrum Medyczne NeuroProtect, Warsaw

011025

S.C. Sana Monitoring Srl, Bucharest

011461

Spitalul Universitar Elias Bucharesti, Bucharest

012071

S.C. Quantum Medical Center Srl, Bucharest

020125

Spitalul Clinic Colentina Bucharest, Neurologie 2, Bucharest

03110

Kyiv City Clinical Hospital #4, Department of Neurology, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Immunic AG

INDUSTRY